Latest news

• FDA approves BMS’ blood cancer CAR T therapy after delay

  BMS, Novartis and Gilead/Kite’s respective CAR T therapies all carry a black box warning for neurotoxicity, as well as cytokine release syndrome – an overreaction of the body’s immune

• AZ, Daiichi Sankyo strengthen case for HER2 candidate

  Although this could lead to a potential black-box warning on the label if the drug is approved, the benefit of a 60.9% response in patients who have already been

• BMS, Acceleron Pharma’s Reblozyl to be reviewed by FDA expert panel

  Some analysts have predicted that Inrebic could also become a $1bn product in myelofibrosis, despite a black-box warning on its label for a serious and life-threatening brain reaction called

• Roche agrees $1.4bn takeover of fibrosis specialist Promedior

  Some analysts think Inrebic could become a $1bn product for myelofibrosis, despite a black-box warning on its label for a serious and life-threatening brain reaction – Wernicke's encephalopathy – that

• J&J’s Invokana gets lifeline with new kidney disease approval

  2016 before the addition of a black-box warning to its label in 2017.